1. Home
  2. MRLN vs SDGR Comparison

MRLN vs SDGR Comparison

Compare MRLN & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MRLN

Merlin Inc. Common Stock

N/A

Current Price

$6.65

Market Cap

915.1M

Sector

Technology

ML Signal

N/A

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$12.18

Market Cap

925.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRLN
SDGR
Founded
2018
1990
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
915.1M
925.8M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
MRLN
SDGR
Price
$6.65
$12.18
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$25.00
$21.00
AVG Volume (30 Days)
1.3M
1.3M
Earning Date
10-28-2021
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.14
EPS
N/A
N/A
Revenue
N/A
$255,869,000.00
Revenue This Year
N/A
$0.76
Revenue Next Year
N/A
$4.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.29
52 Week Low
$5.88
$10.95
52 Week High
$17.00
$27.63

Technical Indicators

Market Signals
Indicator
MRLN
SDGR
Relative Strength Index (RSI) 39.46 48.58
Support Level $6.22 $11.18
Resistance Level $17.00 $13.36
Average True Range (ATR) 1.00 0.62
MACD -0.30 -0.09
Stochastic Oscillator 19.22 36.29

Price Performance

Historical Comparison
MRLN
SDGR

About MRLN Merlin Inc. Common Stock

Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: